Benefits of respiratory solutions designed to combat the effects of air pollution will be demonstrated
Aptar Pharma will exhibit at CPhI China 2018, which will be held at the Shanghai New International Exhibition Center, Shanghai, China, from June 20-22.
At Booth No. N5F30, Aptar Pharma will be introducing new market innovations in inhalation drug delivery for the Chinese market, demonstrating the benefits of these exciting respiratory solutions designed to combat the effects of air pollution.
The company will showcase their innovative connected device portfolio, which covers application fields such as respiratory and eye care. Visitors will have the opportunity to discover these intuitive devices featuring fully-connected functionality and software integration for improving patient health outcomes.
Another highlight of the booth will be Aptar Pharma’s drug delivery systems expertise in dermal innovation. Specialists will be on hand to discuss the newly enhanced dispensing solutions for Aptar Pharma’s Airless Dermal Drug Delivery Systems, providing insight into how their technologies and features can support pharmaceutical professionals’ drug formulations and consumer products.
In addition to exhibiting, Aptar Pharma is proud to be hosting a half day seminar on June 22, featuring two Aptar Pharma experts who will present the following interactive sessions:
‘Healthy Nose, Healthy Life: A Glance at Global Successful Products for Upper Respiratory Health’ with Guenter Nadler, Director Business Development, Consumer Health Care Division from 9.30-10.30am
‘Say No to Preservatives: Package Innovation for Ophthalmic & Dermal Products’ with Tianjiao Fu, Business Development Manager China, Pharma Sales from 10.30-11.10am
A Q&A session will follow the seminar, which will take place at location N8 in Meeting Room D from 9.30am to 12.00pm.
CPhI China is Asia’s leading trade and networking platform covering the entire pharma industry chain and welcomes over 40,000 experts from over 120 countries to network and collaborate on the forthcoming trends for China’s pharma market.